NCT06389500

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Hepatic Arterial Infusion Chemotherapy Combined With Adebrelimab and Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer: a Single-arm, Exploratory Clinical Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Harbin Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, exploratory, phase II trial to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib for borderline resectable, locally advanced biliary tract cancer.

Detailed description

This study plans to recruit 30 patients with borderline resectable, locally advanced biliary tract cancer who have not received treatment， abserve and evaluate the efficacy and safety of hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib.

Conditions

• Biliary Tract Cancer

Interventions

Type	Name	Description
DRUG	Adebrelimab	Adebrelimab, IV
DRUG	Lenvatinib	Lenvatinib, PO
PROCEDURE	Hepatic Arterial Infusion Chemotherapy	GC regimen±5-FU

Timeline

• Start date: 2024-05-01
• Primary completion: 2027-05-01
• Completion: 2028-05-01
• First posted: 2024-04-29
• Last updated: 2024-04-29